Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

Rhea-AI Summary

Kymera Therapeutics, Inc. (NASDAQ: KYMR) will host a virtual Immunology R&D Day on January 4, 2024, to provide an update on its emerging pipeline of high-value immunology programs, new target disclosures, preclinical data, and clinical study initiation timing.

Company to provide update on its emerging pipeline of high-value immunology programs

WATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&D Day that the Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m. ET. The R&D Day will focus on the Company’s emerging pipeline of high-value immunology programs, including new target disclosures, supporting preclinical data and timing to clinical study initiation.

To join the webcast, please visit this link, or the “Events and Presentations” page of the Investors section on the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics

Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera’s initial programs target IRAK4 and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” company by Fierce Biotech and has been recognized by both the Boston Globe and the Boston Business Journal as one of Boston’s top workplaces. For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn.

Investor Contact:	Media Contact:
Justine Koenigsberg	Todd Cooper
Vice President, Investor Relations	Senior Vice President, Corporate Affairs
investors@kymeratx.com	media@kymeratx.com
857-285-5300	857-285-5300

FAQ

What is Kymera Therapeutics, Inc.'s ticker symbol?

Kymera Therapeutics, Inc.'s ticker symbol is NASDAQ: KYMR.

When will Kymera Therapeutics, Inc. host the virtual Immunology R&D Day?

Kymera Therapeutics, Inc. will host the virtual Immunology R&D Day on January 4, 2024.

What will be the focus of Kymera Therapeutics, Inc.'s R&D Day?

The R&D Day will focus on the Company’s emerging pipeline of high-value immunology programs, including new target disclosures, supporting preclinical data, and timing to clinical study initiation.

Where can I join the webcast for Kymera Therapeutics, Inc.'s R&D Day?

To join the webcast, please visit the 'Events and Presentations' page of the Investors section on the Company’s website at www.kymeratx.com.

Will the webcast for Kymera Therapeutics, Inc.'s R&D Day be available for replay?

Yes, a replay of the webcast will be archived and available following the event.